US47010C4096
© ACCESSWIRE
10.12.2025
JAGX
LISTED
NASDAQ
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
News Preview
Conditional approval extended through December 2026 for the treatment of CID in dogsCID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49 more expected SAN FRANCISCO, CA / ACCESS Newswire / December 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that th...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
JAGX
LISTED
NASDAQ
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
News Preview
Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to registerInitial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to m...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.12.2025
JAGX
LISTED
NASDAQ
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
News Preview
Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia®A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary emergency hospitals SAN FRAN...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
24.11.2025
JAGX
LISTED
NASDAQ
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
News Preview
This new IP supports crofelemer's global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer - supporting Jaguar's strategy to secure non-dilutive partnership fundingRecent publication by members of Jaguar's Scientific Advisory Board and other...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESSWIRE
20.11.2025
JAGX
LISTED
NASDAQ
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
News Preview
Crofelemer can potentially extend lives of MVID patients - infants and children who face the lethal natural history of the diseaseParenteral support reduction of up to 37% is groundbreaking; No approved treatments exist for MVID in any region SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 20, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.11.2025
JAGX
LISTED
NASDAQ
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
News Preview
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.11.2025
JAGX
LISTED
NASDAQ
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates
News Preview
Click here to registerCompany plans to file its Earnings Report on November 14, 2025 on Form 10-Q for the quarter ended September 30, 2025 SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, November 17, 2025, at 8:30 a.m. Eastern to...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.11.2025
JAGX
LISTED
NASDAQ
Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting
News Preview
Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to surviveGroundbreaking PS reduction of up to 37% is unprecedented; No approved treatments exist for MVID SAN FRANCISCO, CA / ACCESS Newswire / November 13, 2025 / Jaguar Health, In...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.11.2025
JAGX
LISTED
NASDAQ
REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrit
News Preview
Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of total parenteral support (PS) in pediatric intestinal failure patients ranging between 12% to 37% SAN FRANCISCO, CA / ACCESS Newswire / November 6, 2025 / Jaguar Health, Inc. (NAS...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.10.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / October 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 20, 2025, the Company granted 600 restricted stock units (RSUs) to New Employee 1, 600 RSUs to New Employee 2, and 300 RSUs to New Employee 3.The RSUs for New Empl...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
JAGX
LISTED
NASDAQ
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
News Preview
Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral nutrition and supplementary IV fluids) of approximately 37% SAN FRANCISCO, CA, AL / ACCESS Newswire / October 6, 2025 / Jaguar Health, Inc. (N...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.09.2025
JAGX
LISTED
NASDAQ
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease
News Preview
The two programs are being conducted under separate Single-Patient Investigational New Drug (sIND) applications in the United States SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
25.09.2025
JAGX
LISTED
NASDAQ
Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
News Preview
Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO, CA / ACCESS Newswire / September 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the ve...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.09.2025
JAGX
LISTED
NASDAQ
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition
News Preview
Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant responder analysis results for crofelemer in the prespecified subgroup of patients with breast cancer from the OnTarget study that were reported at the Multinational Association of Supportive Care in Cancer 2025 Annual Meet...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
23.09.2025
JAGX
LISTED
NASDAQ
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
News Preview
SAN FRANCISCO, CA / ACCESS Newswire / September 23, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, September 25, 2025 at the Emerging Growth Conference and virtually on Tuesday, September 30, 2025 at the Lytham Partners Fall 2025 Conference.Part...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.09.2025
JAGX
LISTED
NASDAQ
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts
News Preview
Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 5, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which takes place September 8-10, 2025.Participation Instruction...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.08.2025
JAGX
LISTED
NASDAQ
Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
News Preview
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogsCompany strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globallyDiarrhea is...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.08.2025
JAGX
LISTED
NASDAQ
Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
News Preview
Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to registerAs announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inc...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.08.2025
JAGX
LISTED
NASDAQ
Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
News Preview
As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID patient by up to 27%; abstract describing results accepted for presentation at upcoming North American Society for Pediatric Gastroenterology, Hepat...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.08.2025
JAGX
LISTED
NASDAQ
Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
News Preview
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 millionMytesi prescription volume increased ap...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.08.2025
JAGX
LISTED
NASDAQ
Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
News Preview
Click here to registerCompany plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Jaguar Health, I...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.07.2025
JAGX
LISTED
NASDAQ
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
News Preview
Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization for general diarrhea globallyDiarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common re...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.06.2025
JAGX
LISTED
NASDAQ
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient
News Preview
As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5%The first two pati...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.06.2025
JAGX
LISTED
NASDAQ
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
News Preview
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurren...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.06.2025
JAGX
LISTED
NASDAQ
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs
News Preview
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogsJaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed s...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.06.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026
News Preview
Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing SAN FRANCISCO, CA / ACCESS Newswire / June 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that the maturity date has been extended fr...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
23.06.2025
JAGX
LISTED
NASDAQ
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
News Preview
Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25%As recently announced, initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) show crofelemer reduced the required t...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.06.2025
JAGX
LISTED
NASDAQ
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
News Preview
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 18, 2025 at the Emerging Growth Conference.Participation Instructions for Jaguar's Virtual Presentation at the Emerging Gr...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.06.2025
JAGX
LISTED
NASDAQ
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
News Preview
Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogsJaguar in discussions with potential partners to license and fund development...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
09.06.2025
JAGX
LISTED
NASDAQ
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
News Preview
Click here to registerDiscussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in company's recently conducted Phase 3 OnTarget trialThe currently estimated US metastatic breast cancer population potentially qualifies as an orphan p...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
09.06.2025
JAGX
LISTED
NASDAQ
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
News Preview
Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapiesThe currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with co...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.06.2025
JAGX
LISTED
NASDAQ
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series
News Preview
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat at 9:00 AM Eastern on Tuesday, June 10, 2025, as part of Lytham Partners' spring 2025 Spotlight Series. The discussion wi...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.05.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
News Preview
SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct offering priced at-the-market...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.05.2025
JAGX
LISTED
NASDAQ
First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
News Preview
As announced, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient with intestinal failure by up to 27%; per the IIT protocol, patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days, but...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.05.2025
JAGX
LISTED
NASDAQ
Jaguar Health Reports First Quarter 2025 Financials
News Preview
The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4 million and 37% versus net Q4 2024 revenue of $3.5 million Mytesi prescription volume increased by approximately 1.8% in Q1 2025 over Q1 2024 and decr...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.05.2025
JAGX
LISTED
NASDAQ
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates
News Preview
Click here to registerCompany plans to file its Earnings Report on May 15, 2025 on Form 10-Q for the quarter ended March 31, 2025 SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / May 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast tomorrow, Thursday, May 15, 2025, at 4:15 p.m. Eastern to r...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.05.2025
JAGX
LISTED
NASDAQ
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
News Preview
Company's Canalevia®-CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2025 / Jaguar Health, Inc. (NASDAQ:J...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.05.2025
JAGX
LISTED
NASDAQ
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
News Preview
Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical GuidanceClick here to access replay of company's April 30, 2025 investor webcast SAN FRANCISCO, CA / ACCESS Newswire / May 7, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today provided an overview of expected Q2 - Q4 2025 catalysts r...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.04.2025
JAGX
LISTED
NASDAQ
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease
News Preview
Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI Congress; Click here to registerThere are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and mal...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.04.2025
JAGX
LISTED
NASDAQ
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
News Preview
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to registerThere are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by se...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
28.04.2025
JAGX
LISTED
NASDAQ
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
News Preview
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to registerThere are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by se...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.04.2025
JAGX
LISTED
NASDAQ
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
News Preview
Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patientsThe...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.04.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
News Preview
The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer SymposiumLate-breaker abstract accepted by MASCC shows additional significant results for...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.04.2025
JAGX
LISTED
NASDAQ
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
News Preview
Gelclair® is the company's third commercialized prescription productOral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task forceNapo's core target patient audiences for Ge...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.04.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 restricted stock units (RSUs) to New Employee 1, 3,600 RSUs to New Employee 2, 600 RSUs to New Employee 3, 100 RSUs to New Employee 4...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.04.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
News Preview
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement.Jaguar's president and chief executive officer Lisa Conte, as well as other members of the Company's board of directors and other C...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
31.03.2025
JAGX
LISTED
NASDAQ
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
News Preview
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-p...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
28.03.2025
JAGX
LISTED
NASDAQ
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
News Preview
Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDAIn dogs undergoing chemotherapy, as is the case with people undergoing cancer treatment, diarrhea is a highly neglected and unmet medical need SAN FRANCISCO, CA / ACCESS Newswire / March 28, 2025 / Jag...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.03.2025
JAGX
LISTED
NASDAQ
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
News Preview
The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer SymposiumLate-breaker abstract recently submitted to the Multinational Association of Supportive...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.03.2025
JAGX
LISTED
NASDAQ
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts
News Preview
Click here to register for Jaguar's March 27 virtual presentation at the Emerging Growth ConferenceClick here to register for Jaguar's March 31 investor webcastCompany plans to file its annual report on March 31, 2025 on Form 10-K for the year ended December 31, 2024 SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc. (NASDAQ...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.03.2025
JAGX
LISTED
NASDAQ
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
News Preview
SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, three other members of the Company's board of directors, and seven other C-suite and senior executives of Jaguar along with selected...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.03.2025
JAGX
LISTED
NASDAQ
Jaguar Health, Inc. Announces Reverse Stock Split
News Preview
Reverse split approved at March 2025 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025 SAN FRANCISCO, CA / ACCESS Newswire / March 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a re...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.03.2025
JAGX
LISTED
NASDAQ
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
News Preview
Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion diseaseFDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.02.2025
JAGX
LISTED
NASDAQ
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
News Preview
Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion diseaseFDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.02.2025
JAGX
LISTED
NASDAQ
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
News Preview
This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regionsAvailability of first IIT proof-of-conce...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.02.2025
JAGX
LISTED
NASDAQ
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
News Preview
Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.02.2025
JAGX
LISTED
NASDAQ
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
News Preview
SAN FRANCISCO, CA / ACCESS Newswire / February 13, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Tuesday, February 18, 2025 at the Emerging Growth Conference.Participation Instructions for Jaguar Health's Virtual Presentation at the Emerging Growth Confe...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.02.2025
JAGX
LISTED
NASDAQ
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
News Preview
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in late 2025/early 2026 SAN FRANCISCO, CA / ACCESS Newswire / February 6, 2025 / Ja...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
03.02.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
News Preview
Trial taking place at Sheikh Khalifa Medical City, a flagship United Arab Emirates hospital and largest teaching medical center in Abu DhabiCrofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVIDProof-of-concept (POC) data generated from...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.01.2025
JAGX
LISTED
NASDAQ
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
News Preview
Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported in up to 85%Crofelemer, approved by the FDA under the brand name Mytesi® for HIV-related diarrhea, has demonstrated a significant benefit i...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
